Provided by Tiger Fintech (Singapore) Pte. Ltd.

Imunon, Inc.

0.8815
+0.02152.50%
Post-market: 0.8800-0.0015-0.17%16:32 EDT
Volume:48.68K
Turnover:41.62K
Market Cap:12.78M
PE:-0.54
High:0.8996
Open:0.8600
Low:0.8316
Close:0.8600
Loading ...

IMUNON Announces New Immunogenicity Data from Phase 1 Clinical Trial of Its DNA Vaccine in Treatment of COVID-19

GlobeNewswire
·
26 Feb

Imunon Inc expected to post a loss of 36 cents a share - Earnings Preview

Reuters
·
25 Feb

BRIEF-Imunon Announces Translational Data From Phase 1/2 Ovation 2 Study Of Imnn-001 In Advanced Ovarian Cancer

Reuters
·
19 Feb

Imunon Is Maintained at Buy by D. Boral Capital

Dow Jones
·
19 Feb

Imunon Announces Translational Data From Phase 1/2 Ovation 2 Study of Imnn-001 in Advanced Ovarian Cancer

THOMSON REUTERS
·
19 Feb

Imunon Inc - Imnn-001 Shows Favorable Safety Profile With No Serious Adverse Events

THOMSON REUTERS
·
19 Feb

Imunon Inc - to Initiate Phase 3 Trial of Imnn-001 in Q1 2025

THOMSON REUTERS
·
19 Feb

IMUNON Announces Translational Data from Phase 1/2 OVATION 2 Study of IMNN-001 in Advanced Ovarian Cancer

GlobeNewswire
·
19 Feb

Imunon Appoints Douglas V. Faller, M.d., Ph.d., as Chief Medical Officer

THOMSON REUTERS
·
10 Feb

IMUNON Appoints Douglas V. Faller, M.D., Ph.D., as Chief Medical Officer

GlobeNewswire
·
10 Feb

IMNN: Gearing Up to Initiate Phase 3 Ovarian Cancer Trial in 1Q25…

Zacks Small Cap Research
·
28 Jan

Imunon Is Maintained at Buy by D. Boral Capital

Dow Jones
·
24 Jan

Imunon Price Target Maintained With a $12.00/Share by HC Wainwright & Co.

Dow Jones
·
20 Dec 2024

BRIEF-Imunon Announces Positive Cmc Meeting With FDA For Imnn-001 In Treatment Of Advanced Ovarian Cancer

Reuters
·
19 Dec 2024

Imunon announces positive outcome of Type C CMC meeting with FDA on IMNN-001

TIPRANKS
·
19 Dec 2024

Imunon Inc - Aligns With FDA on Cmc Strategy for Phase 3 Trial

THOMSON REUTERS
·
19 Dec 2024

Imunon Announces Positive Cmc Meeting With FDA for Imnn-001 in Treatment of Advanced Ovarian Cancer

THOMSON REUTERS
·
19 Dec 2024

Imunon Inc: on Track to Initiate Phase 3 Pivotal Trial of Imnn-001 in Q1 of 2025

THOMSON REUTERS
·
19 Dec 2024

IMUNON Announces Positive CMC Meeting with FDA for IMNN-001 in Treatment of Advanced Ovarian Cancer

GlobeNewswire
·
19 Dec 2024

Imunon Price Target Maintained With a $12.00/Share by HC Wainwright & Co.

Dow Jones
·
11 Dec 2024